Wide Ranks

BDTX

Black Diamond Therapeutics, Inc

2.57

Top Statistics
Market Cap 145 M Forward PE -2.05 Revenue Growth 0.00 %
Current Ratio 5.55 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.6880 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 112 M Total Cash Per Share 1.99 Total Debt 22 M
Total Debt To Equity 23.61 Current Ratio 5.55 Book Value Per Share 1.72
All Measures
Short Ratio 980.00 % Message Board Id finmb_424913244 Shares Short Prior Month 7 M
Return On Equity -0.6309 City Cambridge Uuid 822eae7d-25a2-3ffc-8b26-04730bb0212d
Previous Close 2.47 First Trade Date Epoch Utc 1 B Book Value 1.72
Beta 2.52 Total Debt 22 M Volume 413240
Price To Book 1.49 Fifty Two Week Low 2.19 Total Cash Per Share 1.99
Shares Short Previous Month Date 1 B Target Median Price 15.50 Max Age 86400
Sand P52 Week Change 0.3133 Target Mean Price 14.50 Net Income To Common -73099000
Short Percent Of Float 0.1766 Implied Shares Outstanding 56 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 467870 Average Volume10days 467870
Total Cash 112 M Next Fiscal Year End 1 B Held Percent Insiders 0.0226
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 2.47 Target Low Price 9.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 3.34 Open 2.48 Free Cashflow -34594624
State MA Dividend Yield 0.00 % Return On Assets -0.3278
Time Zone Short Name EST Trailing Eps -1.33 Day Low 2.46
Address1 One Main Street Shares Outstanding 56 M Price Hint 4
Target High Price 20.00 Website https://www.blackdiamondtherapeutics.com 52 Week Change 0.0983
Average Volume 1 M Forward Eps -1.22 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 541.70 % Is_sp_500 False
Regular Market Day High 2.58 Profit Margins 0.00 % Debt To Equity 23.61
Fifty Two Week High 7.66 Day High 2.58 Shares Short 5 M
Regular Market Open 2.48 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.1049 Operating Cashflow -61204000
Currency USD Time Zone Full Name America/New_York Market Cap 145 M
Is_nasdaq_100 False Zip 02142 Quote Type EQUITY
Industry Biotechnology Long Name Black Diamond Therapeutics, Inc. Regular Market Day Low 2.46
Held Percent Institutions 0.9899 Current Price 2.57 Address2 14th Floor
Enterprise To Ebitda -0.6880 Financial Currency USD Current Ratio 5.55
Industry Disp Biotechnology Number Of Analyst Opinions 6 Country United States
Float Shares 44 M Two Hundred Day Average 4.82 Enterprise Value 55 M
Forward PE -2.05 Regular Market Volume 413240 Ebitda -81017000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.

The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.

It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial.

In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage.

The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018.

Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.